144 related articles for article (PubMed ID: 19789063)
1. Guiding clinical decisions on abdominal obesity and cardiometabolic risk.
Nesto RW; Nelinson DS; Pagotto U
Clin Cornerstone; 2009; 9(4):43-52; discussion 53-4. PubMed ID: 19789063
[TBL] [Abstract][Full Text] [Related]
2. Cardiometabolic risk improvement in response to a 3-yr lifestyle modification program in men: contribution of improved cardiorespiratory fitness vs. weight loss.
Borel AL; Nazare JA; Baillot A; Alméras N; Tremblay A; Bergeron J; Poirier P; Després JP
Am J Physiol Endocrinol Metab; 2017 Apr; 312(4):E273-E281. PubMed ID: 28028035
[TBL] [Abstract][Full Text] [Related]
3. Overweight and obesity: the pathogenesis of cardiometabolic risk.
Bray GA; Clearfield MB; Fintel DJ; Nelinson DS
Clin Cornerstone; 2009; 9(4):30-40; discussion 41-2. PubMed ID: 19789062
[TBL] [Abstract][Full Text] [Related]
4. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes.
López-Jaramillo P; Gómez-Arbeláez D; López-López J; López-López C; Martínez-Ortega J; Gómez-Rodríguez A; Triana-Cubillos S
Horm Mol Biol Clin Investig; 2014 Apr; 18(1):37-45. PubMed ID: 25389999
[TBL] [Abstract][Full Text] [Related]
5. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options.
Cannon CP; Kumar A
Clin Cornerstone; 2009; 9(4):55-68; discussion 69-71. PubMed ID: 19789064
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis.
Wanderley Rocha DR; Jorge AR; Braulio VB; Arbex AK; Marcadenti A
Curr Diabetes Rev; 2017; 13(1):11-18. PubMed ID: 26467189
[TBL] [Abstract][Full Text] [Related]
8. Obesity as a disease state: a new paradigm for diagnosis and treatment.
Aronne LJ; Nelinson DS; Lillo JL
Clin Cornerstone; 2009; 9(4):9-25; discussion 26-9. PubMed ID: 19789061
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for modifying cardiometabolic risk factors.
Aronne LJ
Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
[TBL] [Abstract][Full Text] [Related]
10. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.
Grams J; Garvey WT
Curr Obes Rep; 2015 Jun; 4(2):287-302. PubMed ID: 26627223
[TBL] [Abstract][Full Text] [Related]
11. Body-mass index, abdominal adiposity, and cardiovascular risk.
Gonçalves FB; Koek M; Verhagen HJ; Niessen WJ; Poldermans D
Lancet; 2011 Jul; 378(9787):227; author reply 228. PubMed ID: 21763933
[No Abstract] [Full Text] [Related]
12. Dissociation of body mass index, excess weight loss and body fat percentage trajectories after 3 years of gastric bypass: relationship with metabolic outcomes.
Gómez-Ambrosi J; Andrada P; Valentí V; Rotellar F; Silva C; Catalán V; Rodríguez A; Ramírez B; Moncada R; Escalada J; Salvador J; Frühbeck G
Int J Obes (Lond); 2017 Sep; 41(9):1379-1387. PubMed ID: 28584299
[TBL] [Abstract][Full Text] [Related]
13. Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome.
Wittwer J; Bradley D
Front Immunol; 2021; 12():612496. PubMed ID: 33717095
[TBL] [Abstract][Full Text] [Related]
14. Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children.
Galcheva SV; Iotova VM; Yotov YT; Bernasconi S; Street ME
Eur J Endocrinol; 2011 Apr; 164(4):553-8. PubMed ID: 21224406
[TBL] [Abstract][Full Text] [Related]
15. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
Lee M; Aronne LJ
Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
[TBL] [Abstract][Full Text] [Related]
16. Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.
Rosenson RS
Cardiology; 2009; 114(3):212-25. PubMed ID: 19641317
[TBL] [Abstract][Full Text] [Related]
17. The Role of Secretory Activity Molecules of Visceral Adipocytes in Abdominal Obesity in the Development of Cardiovascular Disease: A Review.
Ragino YI; Stakhneva EM; Polonskaya YV; Kashtanova EV
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32121175
[TBL] [Abstract][Full Text] [Related]
18. Association between exercise-induced change in body composition and change in cardiometabolic risk factors in postmenopausal South Asian women.
Lesser IA; Guenette JA; Hoogbruin A; Mackey DC; Singer J; Gasevic D; Lear SA
Appl Physiol Nutr Metab; 2016 Sep; 41(9):931-7. PubMed ID: 27507007
[TBL] [Abstract][Full Text] [Related]
19. Adding anthropometric measures of regional adiposity to BMI improves prediction of cardiometabolic, inflammatory and adipokines profiles in youths: a cross-sectional study.
Samouda H; de Beaufort C; Stranges S; Guinhouya BC; Gilson G; Hirsch M; Jacobs J; Leite S; Vaillant M; Dadoun F
BMC Pediatr; 2015 Oct; 15():168. PubMed ID: 26497052
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management.
Neeland IJ; Poirier P; Després JP
Circulation; 2018 Mar; 137(13):1391-1406. PubMed ID: 29581366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
